Drug intelligence / Profile preview

GEM307

Development stage: Preclinical
Lead developer: Disc Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GEM307 is an agonistic monoclonal antibody that targets complement factor H (CFH). It was initially developed by Gemini Therapeutics and is now being developed by Disc Medicine following a merger. The drug acts as a CFH stimulant, aiming to modulate the complement system. Its primary focus appears to be on systemic diseases where complement dysregulation plays a role, though specific indications have not been disclosed in detail. As of the latest updates, its highest development status is preclinical with no reported clinical trials in kidney disorders or other specific diseases[1][2][6].

Targets

CFH (Complement factor H)

Beyond the preview

Go deeper on GEM307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEM307.

Explore the full profile